{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:42:32Z","timestamp":1794008552952,"version":"4.8.0"},"reference-count":159,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2025-25404986"],"award-info":[{"award-number":["RS-2025-25404986"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Materials Today Bio"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.mtbio.2026.102774","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:20:00Z","timestamp":1767774000000},"page":"102774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Programmable lipid nanoparticles for RNA therapeutics: Design principles and clinical translation"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3267-3464","authenticated-orcid":false,"given":"Mahdi","family":"Navid Talemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4184-5670","authenticated-orcid":false,"given":"Marzieh","family":"Ramezani Farani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4513-9295","authenticated-orcid":false,"given":"Naiyereh","family":"Alipour Eskandani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3681-6771","authenticated-orcid":false,"given":"Danial","family":"Mirzaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5164-8606","authenticated-orcid":false,"given":"Iraj","family":"Alipourfard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1612-4473","authenticated-orcid":false,"given":"Yun Suk","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.mtbio.2026.102774_bib1","article-title":"Advancements in clinical RNA therapeutics: present developments and prospective outlooks","volume":"5","author":"Saw","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"6","key":"10.1016\/j.mtbio.2026.102774_bib2","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.mtbio.2026.102774_bib3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-024-00943-2","article-title":"Frameworks for transformational breakthroughs in RNA-Based medicines","volume":"23","author":"Androsavich","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10432","key":"10.1016\/j.mtbio.2026.102774_bib4","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S0140-6736(23)02444-3","article-title":"mRNA-based therapeutics: looking beyond COVID-19 vaccines","volume":"403","author":"Parhiz","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.mtbio.2026.102774_bib5","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"24","key":"10.1016\/j.mtbio.2026.102774_bib19","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and safety of an mRNA-Based RSV PreF vaccine in older adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.mtbio.2026.102774_bib20","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1039\/D4NR00019F","article-title":"Advances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines","volume":"16","author":"Wu","year":"2024","journal-title":"Nanoscale"},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mtbio.2026.102774_bib21","author":"Kasiewicz"},{"issue":"2","key":"10.1016\/j.mtbio.2026.102774_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102224","article-title":"Unlocking the therapeutic potential of locked nucleic acids through lipid nanoparticle delivery","volume":"35","author":"Qassem","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.mtbio.2026.102774_bib23","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.omtn.2023.05.005","article-title":"Lipid nanoparticle delivery limits antisense oligonucleotide activity and cellular distribution in the brain after intracerebroventricular injection","volume":"32","author":"Byrnes","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"2","key":"10.1016\/j.mtbio.2026.102774_bib24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/ehjcvp\/pvad103","article-title":"VERVE-101: a promising CRISPR-based gene editing therapy that reduces LDL-C and PCSK9 levels in HeFH patients","volume":"10","author":"Horie","year":"2024","journal-title":"European Heart Journal - Cardiovascular Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.mtbio.2026.102774_bib25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-023-00833-2","article-title":"Lipid nanoparticle-enabled intracellular delivery of prime editors","volume":"25","author":"Herrera-Barrera","year":"2023","journal-title":"AAPS J."},{"issue":"4","key":"10.1016\/j.mtbio.2026.102774_bib10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"issue":"6","key":"10.1016\/j.mtbio.2026.102774_bib18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.mtbio.2026.102774_bib6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","article-title":"The 60-year evolution of lipid nanoparticles for nucleic acid delivery","volume":"23","author":"Cullis","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"19","key":"10.1016\/j.mtbio.2026.102774_bib7","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","article-title":"Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase","volume":"385","author":"El Sahly","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"27","key":"10.1016\/j.mtbio.2026.102774_bib8","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"52","key":"10.1016\/j.mtbio.2026.102774_bib11","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109256118","article-title":"On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles","volume":"118","author":"Dilliard","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mtbio.2026.102774_bib12","article-title":"Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy","author":"Witten","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.102774_bib13","first-page":"546","article-title":"Biocompatibility and immunomodulation of MXenes for targeted delivery of bioactive agents and drugs","volume":"55","author":"Ramezani Farani","year":"2026","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.mtbio.2026.102774_bib14","article-title":"Synthesizing lipid nanoparticles by turbulent flow in confined impinging jet mixers","volume":"210","author":"Subraveti","year":"2024","journal-title":"JoVE J."},{"key":"10.1016\/j.mtbio.2026.102774_bib15","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1038\/mtna.2012.28","article-title":"Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA, molecular therapy","volume":"1","author":"Belliveau","year":"2012","journal-title":"Nucleic acids"},{"key":"10.1016\/j.mtbio.2026.102774_bib16","author":"Liu"},{"issue":"12","key":"10.1016\/j.mtbio.2026.102774_bib17","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"issue":"34","key":"10.1016\/j.mtbio.2026.102774_bib26","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"3","key":"10.1016\/j.mtbio.2026.102774_bib27","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jamaneurol.2024.4631","article-title":"Five-year results with patisiran for hereditary transthyretin amyloidosis with polyneuropathy: a randomized clinical trial with open-label extension","volume":"82","author":"Adams","year":"2025","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltae011","article-title":"Systematic review and meta-analysis of COVID-19 mRNA vaccine effectiveness against hospitalizations in adults","volume":"4","author":"Wong","year":"2024","journal-title":"Immunotherapy Advances"},{"issue":"4","key":"10.1016\/j.mtbio.2026.102774_bib29","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1208\/s12248-014-9598-3","article-title":"Understanding pharmaceutical quality by design","volume":"16","author":"Yu","year":"2014","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41541-021-00322-7","article-title":"Quality by design modelling to support rapid RNA vaccine production against emerging infectious diseases","volume":"6","author":"van de Berg","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.mtbio.2026.102774_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.biologicals.2023.101700","article-title":"Regulatory perspective for quality evaluation of lipid nanoparticle-based mRNA vaccines in China","volume":"84","author":"Lu","year":"2023","journal-title":"Biologicals"},{"issue":"3","key":"10.1016\/j.mtbio.2026.102774_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103505","article-title":"Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids","volume":"28","author":"Mendon\u00e7a","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.mtbio.2026.102774_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113945","article-title":"Impact of ionizable lipid type on the pharmacokinetics and biodistribution of mRNA-lipid nanoparticles after intravenous and subcutaneous injection","volume":"384","author":"Ren","year":"2025","journal-title":"J. Contr. Release"},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib34","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/s42003-021-02441-2","article-title":"Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration","volume":"4","author":"Carrasco","year":"2021","journal-title":"Commun. Biol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib35","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1021\/acs.molpharmaceut.4c00426","article-title":"Calculating apparent pKa values of ionizable lipids in lipid nanoparticles","volume":"22","author":"Hamilton","year":"2025","journal-title":"Mol. Pharm."},{"issue":"34","key":"10.1016\/j.mtbio.2026.102774_bib36","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib37","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1021\/acs.molpharmaceut.4c00426","article-title":"Calculating apparent pK(a) values of ionizable lipids in lipid nanoparticles","volume":"22","author":"Hamilton","year":"2025","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.mtbio.2026.102774_bib38","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib39","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","article-title":"Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery","volume":"18","author":"Wang","year":"2023","journal-title":"Nat. Protoc."},{"issue":"2","key":"10.1016\/j.mtbio.2026.102774_bib40","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s13346-023-01402-y","article-title":"Inhalable dry powder product (DPP) of mRNA lipid nanoparticles (LNPs) for pulmonary delivery","volume":"14","author":"Sarode","year":"2024","journal-title":"Drug Delivery and Translational Research"},{"key":"10.1016\/j.mtbio.2026.102774_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113879","article-title":"A perspective on the apparent pKa of ionizable lipids in mRNA-LNPs","volume":"384","author":"Simonsen","year":"2025","journal-title":"J. Contr. Release"},{"issue":"17","key":"10.1016\/j.mtbio.2026.102774_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202206968","article-title":"Biodegradable cationic and ionizable cationic lipids: a roadmap for safer pharmaceutical excipients","volume":"19","author":"J\u00f6rgensen","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.mtbio.2026.102774_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115446","article-title":"Breaking the final barrier: evolution of cationic and ionizable lipid structure in lipid nanoparticles to escape the endosome","volume":"214","author":"Mrksich","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mtbio.2026.102774_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113906","article-title":"Impact of tail unsaturation in ionizable lipids on mRNA delivery efficiency and immunogenicity of lipid nanoparticles","volume":"384","author":"Ge","year":"2025","journal-title":"J. Contr. Release"},{"issue":"11","key":"10.1016\/j.mtbio.2026.102774_bib45","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/s41551-024-01256-w","article-title":"Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles by binding to the receptors TLR4 and CD1d","volume":"8","author":"Chaudhary","year":"2024","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib54","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41541-023-00751-6","article-title":"Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability","volume":"8","author":"Zhang","year":"2023","journal-title":"npj Vaccines"},{"key":"10.1016\/j.mtbio.2026.102774_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"27","key":"10.1016\/j.mtbio.2026.102774_bib56","doi-asserted-by":"crossref","first-page":"11647","DOI":"10.1039\/D3NR00987D","article-title":"Structural insights on ionizable Dlin-MC3-DMA lipids in DOPC layers by combining accurate atomistic force fields, molecular dynamics simulations and neutron reflectivity","volume":"15","author":"Ibrahim","year":"2023","journal-title":"Nanoscale"},{"issue":"2","key":"10.1016\/j.mtbio.2026.102774_bib57","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.102774_bib58","doi-asserted-by":"crossref","DOI":"10.1039\/C9NR02297J","article-title":"Ionizable amino lipid interactions with POPC: implications for lipid nanoparticle function","volume":"11","author":"Ramezanpour","year":"2019","journal-title":"Nanoscale"},{"issue":"4","key":"10.1016\/j.mtbio.2026.102774_bib59","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3390\/vaccines13040339","article-title":"Exploring the challenges of lipid nanoparticle development: the in Vitro\u2013In vivo correlation gap","volume":"13","author":"Lindsay","year":"2025","journal-title":"Vaccines"},{"issue":"11","key":"10.1016\/j.mtbio.2026.102774_bib60","doi-asserted-by":"crossref","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","article-title":"Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs","volume":"15","author":"Kauffman","year":"2015","journal-title":"Nano Lett."},{"key":"10.1016\/j.mtbio.2026.102774_bib61","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jconrel.2020.06.030","article-title":"Theranostic dendrimer-based lipid nanoparticles containing PEGylated BODIPY dyes for tumor imaging and systemic mRNA delivery in vivo","volume":"325","author":"Xiong","year":"2020","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.102774_bib46","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.addr.2016.01.022","article-title":"The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery","volume":"99","author":"Cheng","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib47","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/s41598-024-52685-1","article-title":"A careful look at lipid nanoparticle characterization: analysis of benchmark formulations for encapsulation of RNA cargo size gradient","volume":"14","author":"Schober","year":"2024","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.mtbio.2026.102774_bib48","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1039\/D0BM01609H","article-title":"Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver","volume":"9","author":"Zhang","year":"2021","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.mtbio.2026.102774_bib49","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jconrel.2024.08.016","article-title":"The role of helper lipids in optimising nanoparticle formulations of self-amplifying RNA","volume":"374","author":"Barbieri","year":"2024","journal-title":"J. Contr. Release"},{"issue":"12","key":"10.1016\/j.mtbio.2026.102774_bib50","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1039\/D0BM01947J","article-title":"Illuminating endosomal escape of polymorphic lipid nanoparticles that boost mRNA delivery","volume":"9","author":"Herrera","year":"2021","journal-title":"Biomater. Sci."},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib51","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41467-020-14527-2","article-title":"Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA","volume":"11","author":"Patel","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.102774_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/s41565-025-01958-5","article-title":"Tailoring the adjuvanticity of lipid nanoparticles by PEG lipid ratio and phospholipid modifications","author":"Vadovics","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.mtbio.2026.102774_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125240","article-title":"Intracellular trafficking of lipid nanoparticles is hindered by cholesterol","volume":"671","author":"Luo","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mtbio.2026.102774_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102586","article-title":"Lipid nanoparticles: a delicate nucleic acid delivery system to be further explored","volume":"61","author":"Ma","year":"2025","journal-title":"Nano Today"},{"issue":"2","key":"10.1016\/j.mtbio.2026.102774_bib63","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3390\/pharmaceutics15020597","article-title":"Effect of PEG anchor and serum on lipid nanoparticles: development of a nanoparticles tracking method","volume":"15","author":"Berger","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib64","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","article-title":"Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery","volume":"18","author":"Wang","year":"2023","journal-title":"Nat. Protoc."},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101436","article-title":"Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism","volume":"33","author":"Hosseini-Kharat","year":"2025","journal-title":"Mol. Ther., Methods Clin. Dev."},{"issue":"4","key":"10.1016\/j.mtbio.2026.102774_bib66","doi-asserted-by":"crossref","first-page":"6709","DOI":"10.1021\/acsnano.0c10064","article-title":"Apolipoprotein E binding drives structural and compositional rearrangement of mRNA-Containing lipid nanoparticles","volume":"15","author":"Sebastiani","year":"2021","journal-title":"ACS Nano"},{"issue":"12","key":"10.1016\/j.mtbio.2026.102774_bib67","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.1021\/acs.nanolett.2c01133","article-title":"Universal barcoding predicts in vivo ApoE-Independent lipid nanoparticle delivery","volume":"22","author":"Da Silva Sanchez","year":"2022","journal-title":"Nano Lett."},{"issue":"4","key":"10.1016\/j.mtbio.2026.102774_bib68","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102083","article-title":"mRNA vaccine trafficking and resulting protein expression after intramuscular administration","volume":"35","author":"Hassett","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"3","key":"10.1016\/j.mtbio.2026.102774_bib70","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/s41565-023-01548-3","article-title":"Combinatorial development of nebulized mRNA delivery formulations for the lungs","volume":"19","author":"Jiang","year":"2024","journal-title":"Nat. Nanotechnol."},{"issue":"11","key":"10.1016\/j.mtbio.2026.102774_bib71","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1039\/D5BM00322A","article-title":"Non-viral mRNA delivery to the lungs","volume":"13","author":"Healy","year":"2025","journal-title":"Biomater. Sci."},{"issue":"4","key":"10.1016\/j.mtbio.2026.102774_bib72","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41565-023-01580-3","article-title":"Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity","volume":"19","author":"Liu","year":"2024","journal-title":"Nat. Nanotechnol."},{"issue":"5","key":"10.1016\/j.mtbio.2026.102774_bib73","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2409572122","article-title":"Rational design and modular synthesis of biodegradable ionizable lipids via the Passerini reaction for mRNA delivery","volume":"122","author":"Xu","year":"2025","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib74","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-55072-6","article-title":"Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.mtbio.2026.102774_bib75","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2311700120","article-title":"Lipid shape and packing are key for optimal design of pH-sensitive mRNA lipid nanoparticles","volume":"121","author":"Tesei","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mtbio.2026.102774_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125571","article-title":"Regulating mRNA endosomal escape through lipid rafts: a review","volume":"675","author":"Wang","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mtbio.2026.102774_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123695","article-title":"Effects of PEG antibodies on in vivo performance of LNP-mRNA vaccines","volume":"650","author":"Yang","year":"2024","journal-title":"Int. J. Pharm."},{"issue":"9","key":"10.1016\/j.mtbio.2026.102774_bib78","doi-asserted-by":"crossref","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","article-title":"Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies","volume":"15","author":"Chen","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.mtbio.2026.102774_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2024.1383038","article-title":"Poly(2-methyl-2-oxazoline) as a polyethylene glycol alternative for lipid nanoparticle formulation","volume":"4","author":"van Zyl","year":"2024","journal-title":"Frontiers in Drug Delivery"},{"key":"10.1016\/j.mtbio.2026.102774_bib80","doi-asserted-by":"crossref","DOI":"10.1038\/s41563-025-02240-8","article-title":"Poly(carboxybetaine) lipids enhance mRNA therapeutics efficacy and reduce their immunogenicity","author":"Luozhong","year":"2025","journal-title":"Nat. Mater."},{"issue":"7","key":"10.1016\/j.mtbio.2026.102774_bib81","doi-asserted-by":"crossref","DOI":"10.1038\/s44222-025-00333-2","article-title":"Zwitterionic polymers as PEG replacements for improved mRNA delivery","volume":"3","author":"Horejs","year":"2025","journal-title":"Nature Reviews Bioengineering"},{"issue":"34","key":"10.1016\/j.mtbio.2026.102774_bib82","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.mtbio.2026.102774_bib83","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2013.66","article-title":"Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles","volume":"2","author":"Mui","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"12","key":"10.1016\/j.mtbio.2026.102774_bib84","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1039\/D2BM01846B","article-title":"Analysis of PEG-lipid anchor length on lipid nanoparticle pharmacokinetics and activity in a mouse model of traumatic brain injury","volume":"11","author":"Waggoner","year":"2023","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.mtbio.2026.102774_bib85","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2012.28","article-title":"Microfluidic synthesis of highly potent limit-size lipid nanoparticles for <em>In Vivo<\/em> delivery of siRNA","volume":"1","author":"Belliveau","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"8","key":"10.1016\/j.mtbio.2026.102774_bib86","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1021\/acs.molpharmaceut.2c01024","article-title":"Delivery and expression of mRNA in the secondary lymphoid organs drive immune responses to lipid Nanoparticle-mRNA vaccines after intramuscular injection","volume":"20","author":"Takanashi","year":"2023","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib87","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1038\/s41467-024-45422-9","article-title":"High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","volume":"15","author":"Xue","year":"2024","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.mtbio.2026.102774_bib88","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41551-023-01030-4","article-title":"Peptide-encoding mRNA barcodes for the high-throughput in vivo screening of libraries of lipid nanoparticles for mRNA delivery","volume":"7","author":"Rhym","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.mtbio.2026.102774_bib89","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jconrel.2023.04.005","article-title":"High-throughput screens identify a lipid nanoparticle that preferentially delivers mRNA to human tumors in vivo","volume":"357","author":"Huayamares","year":"2023","journal-title":"J. Contr. Release"},{"issue":"12","key":"10.1016\/j.mtbio.2026.102774_bib90","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1016\/j.xphs.2024.09.015","article-title":"Review of machine learning for lipid nanoparticle formulation and process development","volume":"113","author":"Dorsey","year":"2024","journal-title":"J. Pharmaceut. Sci."},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib91","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.1038\/s41467-024-50093-7","article-title":"Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation","volume":"15","author":"Su","year":"2024","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.mtbio.2026.102774_bib92","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1038\/s41596-024-01134-4","article-title":"mRNA lipid nanoparticle formulation, characterization and evaluation","volume":"20","author":"Ma","year":"2025","journal-title":"Nat. Protoc."},{"issue":"10","key":"10.1016\/j.mtbio.2026.102774_bib93","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.tibtech.2022.03.012","article-title":"Quality by design for enabling RNA platform production processes","volume":"40","author":"Daniel","year":"2022","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.mtbio.2026.102774_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125520","article-title":"Process development of tangential flow filtration and sterile filtration for manufacturing of mRNA-lipid nanoparticles: a study on membrane performance and filtration modeling","volume":"675","author":"Wu","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mtbio.2026.102774_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.memsci.2024.122965","article-title":"Development of a new modeling framework to describe sterile filtration of mRNA-Lipid nanoparticles","volume":"706","author":"Messerian","year":"2024","journal-title":"J. Membr. Sci."},{"issue":"49","key":"10.1016\/j.mtbio.2026.102774_bib96","doi-asserted-by":"crossref","first-page":"7307","DOI":"10.1016\/j.vaccine.2023.10.027","article-title":"Key considerations for the development of novel mRNA candidate vaccines in LMICs: a WHO\/MPP mRNA technology transfer programme meeting report","volume":"41","author":"Gsell","year":"2023","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.mtbio.2026.102774_bib97","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3390\/vaccines13050473","article-title":"Considerations for mRNA product development, regulation and deployment across the lifecycle","volume":"13","author":"Skerritt","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.mtbio.2026.102774_bib98","doi-asserted-by":"crossref","DOI":"10.1093\/rb\/rbaf023","article-title":"Development of lyophilized mRNA-LNPs with high stability and transfection efficiency in specific cells and tissues","volume":"12","author":"Wang","year":"2025","journal-title":"Regen. Biomater."},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib99","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41541-025-01253-3","article-title":"Trehalose-loaded LNPs enhance mRNA stability and bridge in vitro in vivo efficacy gap","volume":"10","author":"Liu","year":"2025","journal-title":"npj Vaccines"},{"issue":"12","key":"10.1016\/j.mtbio.2026.102774_bib100","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.3390\/molecules28124836","article-title":"The effect of ethanol on lipid nanoparticle stabilization from a molecular dynamics simulation perspective","volume":"28","author":"Hardianto","year":"2023","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.mtbio.2026.102774_bib101","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1039\/D3LC00821E","article-title":"Microfluidic synthesis of lipid-based nanoparticles for drug delivery: recent advances and opportunities","volume":"24","author":"Mehraji","year":"2024","journal-title":"Lab Chip"},{"issue":"3","key":"10.1016\/j.mtbio.2026.102774_bib102","doi-asserted-by":"crossref","DOI":"10.1063\/5.0150345","article-title":"Microfluidic approaches for producing lipid-based nanoparticles for drug delivery applications","volume":"4","author":"Piunti","year":"2023","journal-title":"Biophysics Reviews"},{"issue":"13","key":"10.1016\/j.mtbio.2026.102774_bib103","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1021\/acs.nanolett.1c01353","article-title":"Scalable mRNA and siRNA lipid nanoparticle production using a parallelized microfluidic device","volume":"21","author":"Shepherd","year":"2021","journal-title":"Nano Lett."},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib105","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1186\/s12951-024-02972-w","article-title":"Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: a quality-by-design approach","volume":"22","author":"Haghighi","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.mtbio.2026.102774_bib104","series-title":"Quality & Regulatory Solutions for PAT in Continuous Manufacturing, Pharmaceutical Engineering","author":"Thompson","year":"2020"},{"issue":"2","key":"10.1016\/j.mtbio.2026.102774_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101463","article-title":"Lipid nanoparticles: composition, formulation, and application","volume":"33","author":"Xu","year":"2025","journal-title":"Mol. Ther., Methods Clin. Dev."},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib107","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1021\/acs.nanolett.1c02503","article-title":"Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells","volume":"22","author":"Billingsley","year":"2022","journal-title":"Nano Lett."},{"key":"10.1016\/j.mtbio.2026.102774_bib108","series-title":"DNA Nanotechnology: Methods and Protocols","first-page":"241","article-title":"A robust post-insertion method for the preparation of targeted lipid nanoparticles","author":"Bimbo","year":"2025"},{"issue":"11","key":"10.1016\/j.mtbio.2026.102774_bib109","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/s41565-024-01765-4","article-title":"Acid-degradable lipid nanoparticles enhance the delivery of mRNA","volume":"19","author":"Zhao","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.mtbio.2026.102774_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113642","article-title":"Analytical characterization of liposomes and other lipid nanoparticles for drug delivery","volume":"192","author":"Fan","year":"2021","journal-title":"J. Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.mtbio.2026.102774_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114571","article-title":"Enhancing RNA encapsulation quantification in lipid nanoparticles: sustainable alternatives to Triton X-100 in the RiboGreen assay","volume":"205","author":"Schultz","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/j.mtbio.2026.102774_bib122","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1021\/acs.analchem.3c04406","article-title":"Quantification of mRNA in lipid nanoparticles using mass spectrometry","volume":"96","author":"Lowenthal","year":"2024","journal-title":"Anal. Chem."},{"issue":"12","key":"10.1016\/j.mtbio.2026.102774_bib112","doi-asserted-by":"crossref","first-page":"11454","DOI":"10.1021\/acsnano.3c01186","article-title":"Correlating the structure and gene silencing activity of oligonucleotide-loaded lipid nanoparticles using small-angle X-ray scattering","volume":"17","author":"Hammel","year":"2023","journal-title":"ACS Nano"},{"issue":"42","key":"10.1016\/j.mtbio.2026.102774_bib113","doi-asserted-by":"crossref","first-page":"E9944","DOI":"10.1073\/pnas.1811276115","article-title":"High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing","volume":"115","author":"Sago","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mtbio.2026.102774_bib114","series-title":"As Revised in August 23","article-title":"Pharmaceutical development, Q8 (2R)","year":"2009"},{"key":"10.1016\/j.mtbio.2026.102774_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124942","article-title":"The influence of citrate buffer molarity on mRNA-LNPs: exploring factors beyond general critical quality attributes","volume":"668","author":"Binici","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mtbio.2026.102774_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2025.114726","article-title":"From in vitro to in vivo: the dominant role of PEG-lipids in LNP performance","volume":"212","author":"Borah","year":"2025","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"8","key":"10.1016\/j.mtbio.2026.102774_bib117","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3390\/pharmaceutics17080950","article-title":"Formulation-driven optimization of PEG-lipid content in lipid nanoparticles for enhanced mRNA delivery in vitro and in vivo","volume":"17","author":"Liu","year":"2025","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.mtbio.2026.102774_bib118","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.3390\/pharmaceutics17091194","article-title":"Examining the impact of storage conditions on the stability of a liquid formulation of mRNA-Loaded lipid nanoparticles","volume":"17","author":"Sato","year":"2025","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib119","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1038\/s41467-025-60040-9","article-title":"Freezing induced incorporation of betaine in lipid nanoparticles enhances mRNA delivery","volume":"16","author":"Cheng","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib120","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1186\/s12951-024-02954-y","article-title":"The role of patient-specific variables in protein corona formation and therapeutic efficacy in nanomedicine","volume":"22","author":"Cisneros","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"24","key":"10.1016\/j.mtbio.2026.102774_bib121","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1007\/s00216-022-04278-y","article-title":"Concentration and composition of the protein corona as a function of incubation time and serum concentration: an automated approach to the protein corona","volume":"414","author":"Poulsen","year":"2022","journal-title":"Anal. Bioanal. Chem."},{"issue":"4","key":"10.1016\/j.mtbio.2026.102774_bib123","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002105","article-title":"Biotechnology: overcoming biological barriers to nucleic acid delivery using lipid nanoparticles","volume":"21","author":"Hamilton","year":"2023","journal-title":"PLoS Biol."},{"issue":"9","key":"10.1016\/j.mtbio.2026.102774_bib124","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1039\/D3NH00145H","article-title":"Selective organ targeting nanoparticles: from design to clinical translation","volume":"8","author":"Li","year":"2023","journal-title":"Nanoscale Horiz."},{"issue":"3","key":"10.1016\/j.mtbio.2026.102774_bib125","doi-asserted-by":"crossref","DOI":"10.1093\/pcmedi\/pbae017","article-title":"Lipid nanoparticle-based mRNA vaccines: a new frontier in precision oncology","volume":"7","author":"Jacob","year":"2024","journal-title":"Precis. Clin. Med."},{"issue":"2","key":"10.1016\/j.mtbio.2026.102774_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102520","article-title":"Targeted mRNA delivery with bispecific antibodies that tether LNPs to cell surface markers","volume":"36","author":"Dietmair","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.mtbio.2026.102774_bib127","doi-asserted-by":"crossref","DOI":"10.3389\/fnano.2024.1330406","article-title":"Development of a minimal PBPK-QSP modeling platform for LNP-mRNA based therapeutics to study tissue disposition and protein expression dynamics","volume":"6","author":"Miyazawa","year":"2024","journal-title":"Frontiers in Nanotechnology"},{"issue":"3","key":"10.1016\/j.mtbio.2026.102774_bib128","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1021\/acs.nanolett.2c04479","article-title":"The transcriptional response to lung-targeting lipid nanoparticles in vivo","volume":"23","author":"Radmand","year":"2023","journal-title":"Nano Lett."},{"key":"10.1016\/j.mtbio.2026.102774_bib129","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jconrel.2024.04.022","article-title":"Lipid nanoparticle-based strategies for extrahepatic delivery of nucleic acid therapies \u2013 challenges and opportunities","volume":"370","author":"Simonsen","year":"2024","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.102774_bib130","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.omtn.2020.01.018","article-title":"Efficient delivery of antisense oligonucleotides using bioreducible lipid nanoparticles in vitro and in vivo","volume":"19","author":"Yang","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"6","key":"10.1016\/j.mtbio.2026.102774_bib131","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib132","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1186\/s12967-024-05957-3","article-title":"From bench to bedside: cutting-edge applications of base editing and prime editing in precision medicine","volume":"22","author":"Xu","year":"2024","journal-title":"J. Transl. Med."},{"issue":"14","key":"10.1016\/j.mtbio.2026.102774_bib133","doi-asserted-by":"crossref","first-page":"13594","DOI":"10.1021\/acsnano.3c02268","article-title":"Ionizable lipid nanoparticles for therapeutic base editing of congenital brain disease","volume":"17","author":"Palanki","year":"2023","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib134","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41551-024-01296-2","article-title":"Safer and efficient base editing and prime editing via ribonucleoproteins delivered through optimized lipid-nanoparticle formulations","volume":"9","author":"Ho\u0142ubowicz","year":"2025","journal-title":"Nat. Biomed. Eng."},{"issue":"9","key":"10.1016\/j.mtbio.2026.102774_bib135","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/s41587-024-02437-3","article-title":"Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR\u2013Cas9 ribonucleoprotein","volume":"43","author":"Chen","year":"2025","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.mtbio.2026.102774_bib136","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1089\/genbio.2023.0045","article-title":"In vivo prime editing by lipid nanoparticle Co-Delivery of chemically modified pegRNA and prime editor mRNA","volume":"2","author":"Chen","year":"2023","journal-title":"GEN Biotechnology"},{"issue":"6656","key":"10.1016\/j.mtbio.2026.102774_bib137","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.ade6967","article-title":"In vivo hematopoietic stem cell modification by mRNA delivery","volume":"381","author":"Breda","year":"2023","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.mtbio.2026.102774_bib138","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307800120","article-title":"Endosomal escape: a bottleneck for LNP-mediated therapeutics","volume":"121","author":"Chatterjee","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.mtbio.2026.102774_bib139","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","article-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"2","key":"10.1016\/j.mtbio.2026.102774_bib140","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","article-title":"Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals","volume":"61","author":"Szebeni","year":"2014","journal-title":"Mol. Immunol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib141","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41541-024-00901-4","article-title":"Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model","volume":"9","author":"England","year":"2024","journal-title":"npj Vaccines"},{"issue":"3","key":"10.1016\/j.mtbio.2026.102774_bib142","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.3390\/ijms24032700","article-title":"A comprehensive review of mRNA vaccines","volume":"24","author":"Gote","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib143","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","article-title":"C. N = possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders","volume":"4","author":"Lauffer","year":"2024","journal-title":"Commun. Med."},{"key":"10.1016\/j.mtbio.2026.102774_bib144","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1006304","article-title":"A perspective on oligonucleotide therapy: approaches to patient customization","volume":"13","author":"Thakur","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"16","key":"10.1016\/j.mtbio.2026.102774_bib145","doi-asserted-by":"crossref","first-page":"9384","DOI":"10.1093\/nar\/gkae648","article-title":"RNA encoded peptide barcodes enable efficient in vivo screening of RNA delivery systems","volume":"52","author":"Odunze","year":"2024","journal-title":"Nucleic Acids Res."},{"issue":"25","key":"10.1016\/j.mtbio.2026.102774_bib146","doi-asserted-by":"crossref","first-page":"16151","DOI":"10.1021\/acsnano.4c01171","article-title":"High-throughput in vivo screening identifies differential influences on mRNA lipid nanoparticle immune cell delivery by administration route","volume":"18","author":"Hamilton","year":"2024","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib147","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1039\/D2LC00463A","article-title":"Liposome manufacturing under continuous flow conditions: towards a fully integrated set-up with in-line control of critical quality attributes","volume":"23","author":"Sheybanifard","year":"2023","journal-title":"Lab Chip"},{"issue":"33","key":"10.1016\/j.mtbio.2026.102774_bib148","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2303567120","article-title":"Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines","volume":"120","author":"Shepherd","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.mtbio.2026.102774_bib149","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3390\/molecules30071629","article-title":"Current analytical strategies for mRNA-Based therapeutics","volume":"30","author":"Camperi","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.mtbio.2026.102774_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2025.465724","article-title":"Characterisation and analysis of mRNA critical quality attributes using liquid chromatography based methods","volume":"1745","author":"Webb","year":"2025","journal-title":"J. Chromatogr. A"},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib151","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41541-023-00766-z","article-title":"Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles in rats","volume":"8","author":"Wang","year":"2023","journal-title":"npj Vaccines"},{"issue":"16","key":"10.1016\/j.mtbio.2026.102774_bib152","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1080\/17435889.2025.2500917","article-title":"The benefits of emerging alternatives to PEG for lipid nanoparticle RNA delivery systems","volume":"20","author":"Berger","year":"2025","journal-title":"Nanomedicine"},{"issue":"17","key":"10.1016\/j.mtbio.2026.102774_bib153","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202304033","article-title":"Substituting poly(ethylene glycol) lipids with Poly(2-ethyl-2-oxazoline) lipids improves lipid nanoparticle repeat dosing","volume":"13","author":"Sanchez","year":"2024","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.mtbio.2026.102774_bib154","doi-asserted-by":"crossref","DOI":"10.1021\/acs.chemrestox.5c00259","article-title":"Advancements in nanomedicine for allergic diseases: diagnosis, toxicity, and therapeutic strategies","author":"Ramezani Farani","year":"2025","journal-title":"Chem. Res. Toxicol."},{"issue":"10","key":"10.1016\/j.mtbio.2026.102774_bib155","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3390\/vaccines12101148","article-title":"Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery","volume":"12","author":"Wang","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.mtbio.2026.102774_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114417","article-title":"Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines","volume":"188","author":"Nakamura","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"11","key":"10.1016\/j.mtbio.2026.102774_bib157","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14112357","article-title":"Stability study of mRNA-Lipid nanoparticles exposed to various conditions based on the evaluation between physicochemical properties and their relation with protein expression ability","volume":"14","author":"Kamiya","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib158","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-70680-4","article-title":"Impact of mixing and shaking on mRNA-LNP drug product quality characteristics","volume":"14","author":"Matthessen","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.mtbio.2026.102774_bib159","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12929-024-01080-z","article-title":"Current landscape of mRNA technologies and delivery systems for new modality therapeutics","volume":"31","author":"Lu","year":"2024","journal-title":"J. Biomed. Sci."}],"container-title":["Materials Today Bio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590006426000165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590006426000165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:12:33Z","timestamp":1774357953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590006426000165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":159,"alternative-id":["S2590006426000165"],"URL":"https:\/\/doi.org\/10.1016\/j.mtbio.2026.102774","relation":{},"ISSN":["2590-0064"],"issn-type":[{"value":"2590-0064","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Programmable lipid nanoparticles for RNA therapeutics: Design principles and clinical translation","name":"articletitle","label":"Article Title"},{"value":"Materials Today Bio","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mtbio.2026.102774","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102774"}}